Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBR759 vs sevelamer hydrochloride for hyperphosphatemia in CKD patients on hemodialysis
2006-001787-23Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2008
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of SBR759 in hyperphosphatemia and chronic kidney disease (CKD) (2 arms), sponsored by Novartis. Primary endpoints: Serum phosphate response at 12 weeks and Safety and tolerability over 12 weeks. Started Jun 2008; status: terminated.
02
Drugs
SBR759
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-001787-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001787-23.